Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility

Japanese Journal of Pharmacology

Volumn 88, Issue 2, 2002, Pages 174-182

  Yoshimi, Kenji ^a   Kozuka, Masao ^a   Sakai, Jyunichi ^a   Iizawa, Tomoko ^a   Shimizu, Yuki ^a   Kaneko, Isao ^a   Kojima, Kouichi ^a   Iwata, Nobuyoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Monoamine oxidase; Parkinson's disease; Reversibility; Tight binding inhibitor

Indexed keywords

3 (2 AMINOETHOXY) 1,2 BENZISOXAZOLE DERIVATIVE; 4 (4 CYANOANILINO) 6,7 DIHYDRO 7 HYDROXY 5H CYCLOPENTA[D]PYRIMIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; LAZABEMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENETHYLAMINE; RS 1519; RS 1524; RS 1530; RS 1533; RS 1592; RS 1594; RS 1610; RS 1622; RS 1627; RS 1636; RS 1650; RS 1653; RS 1655; SELEGILINE; SEROTONIN; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG EXPOSURE; DRUG SELECTIVITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE;

EID: 0036125138     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.88.174     Document Type: Article

References (33)

1. New directions in monoamine oxidase A and B selective inhibitors and substrates
2. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A
3. Determination of regions important for monoamine oxidase (MAO) A and B substrate and inhibitor selectivities
4. Selective inhibitors and computer modelling of the active site of monoamine oxidase
5. The monoamine oxidase inhibiting properties of CGP 11305 A
6. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain
7. Pharmacology of the new reversible inhibitor of monoamine oxidase A, RS-8359
8. The pharmacology of B-type selective monoamine oxidase inhibitors; Milestones in (-)-deprenyl research
9. Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme
10. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition
11. A sensitive and specific assay for the estimation of monoamine oxidase
12. Protein measurement with the Folin phenol reagent
13. Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes
14. The value of the reserpine test in psychopharmacology
15. Beta-phenylethylamine and locomotor activity in mice. Interaction with catecholaminergic neurones and receptors
16. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): A dose ranging study with the reversible inhibitor Ro 19-6327
17. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites
18. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide
19. Monoamine oxidase inhibitors. A perspective on their use in the elderly
20. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease
21. MAO-B inhibition in rabbit tissues and in human platelets by Ro 19-6327 shows similar time-course
22. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease
23. Experience with tranylcypromine in early Parkinson's disease
24. Treatment of major depression and Parkinson's disease with combined phenelzine and amantadine
25. Phenelzine treatment of depression in Parkinson's disease
26. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: Biochemical and clinical observations
27. Depression, intellectual impairment, and Parkinson disease
28. Depression and dementia in Parkinson's disease. Catecholamine changes in the locus ceruleus, a basis for therapy
29. Depression in Parkinson's disease. Pharmacological characteristics and treatment
30. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease
31. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease
32. Distinct monoamine oxidase A and B populations in primate brain
33. Molecular neuroanatomy of monoamine oxidases in human brainstem